Is a complete ELVN research report available?

No complete published report is available for Enliven Therapeutics, Inc. (ELVN) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Enliven Therapeutics, Inc. (ELVN)

NASDAQ: ELVN · USD

$53.0

+0.14 (+0.3%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-27 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ELVN analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	3.7B
Net income (ttm)	-98.8M
EPS (ttm)	-$1.65
Shares out	69.8M
Volume	368,754
Beta	0.26
Price target	$66.9	+26.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -98.8M
EPS (ttm): -$1.65
Market cap: 3.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ELVN indicators

Market & fundamental data

Available fields

183

Groups with data

Currency

USD

Showing 183 of 183 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001672619
Company name	Enliven Therapeutics, Inc.
Country	United States
Country code	US
Cusip	29337E102
Employees	61
Employees Change	-4%
Employees Change Percent	-6.15
Enterprise value	$3.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-03-12
Isin	US29337E1029
Last refreshed	2026-07-27
Market cap	$3.7B
Market cap category	Mid-Cap
Price	$52.95
Price currency	USD
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2834
Symbol	ELVN
Website	https://www.enliventherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.67%
FCF yield	-1.77%
P/B ratio	7.11x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-98.8M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROA	-18.86
Roa5y	-21.36
ROCE	-25.54
ROE	-26.64
Roe5y	-33.35
ROIC	-19.49

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	137.05%
Cagr3y	40.15%
EPS Growth Quarters	1
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$464.9M
Cash	$452.4M
Current Assets	$463.1M
Current Liabilities	$11.5M
Debt	$302,000
Debt Equity	$0
Equity	$453.4M
Liabilities	$11.5M
Long Term Assets	$1.7M
Long Term Liabilities	$0
Net Cash	$452.1M
Net Cash By Market Cap	$12.23
Net Cash Growth	56.5%
Net Debt Equity	$-1
Tangible Book Value	$453.4M
Tangible Book Value Per Share	$7.45
WACC	5.67

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	40.32
Net Working Capital	$-449,000
Quick ratio	39.38
Working Capital	$451.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.96%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	136.91%
200-day SMA	31.98
3Y total return	175.35%
50-day SMA	45.32
50-day SMA vs 200-day SMA	50over200
All Time High	54.88
All Time High Change	-3.52%
All Time High Date	2026-07-21
All Time Low	9.8
All Time Low Change	440.31%
All Time Low Date	2023-12-12
ATR	2.61
Beta	0.26
Beta1y	1
Beta2y	0.92
Ch YTD	243.8
High	53.71
High52	54.88
High52 Date	2026-07-21
High52ch	-3.52%
Low	51.74
Low52	14.79
Low52 Date	2026-01-06
Low52ch	258.13%
Ma50ch	16.83%
Premarket Change Percent	-0.87
Premarket Price	$52.35
Premarket Volume	220
Price vs 200-day SMA	65.59%
RSI	59.92
RSI Monthly	75.98
RSI Weekly	70.03
Sharpe ratio	1.39x
Sortino ratio	2.94
Total Return	-21.96%
Tr YTD	243.8
Tr1m	8.95%
Tr1w	-0.47%
Tr3m	20.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	7
Analyst Price Target Top	$64.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.37
Operating Income	$-115.8M
Price target	$66.89
Price Target Change	$26.33
Price Target Change Top	$22.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	61,070,875%
Float Percent	87.47%
Shares Insiders	2.83%
Shares Institutions	78.39%
Shares Out	69,822,989
Shares Qo Q	0.94%
Shares Yo Y	21.96%
Short Float	13.96%
Short Ratio	3.49
Short Shares	12.21

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-100.2M
Average Volume	1,196,610.75x
Bv Per Share	7.45
CAPEX	$-138,000
Ch1m	8.95
Ch1w	-0.47
Ch1y	136.9
Ch3m	20.64
Ch3y	175.4
Ch6m	105.4
Change	0.27%
Change From Open	-0.38
Close	52.81
Days Gap	0.64
Depreciation Amortization	203,000
Dollar Volume	19,525,524.3
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-115.8M
EBITDA	$-115.5M
EPS	$-1.65
F Score	2
FCF	$-65.6M
FCF EV Yield	-2.02x
FCF Per Share	$-0.94
Financing CF	228,686,000
Fiscal Year End	December
Founded	2,016
Investing CF	-132,742,000
Ipr	230.9
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-03
Ma150	35.76
Ma150ch	48.07%
Ma20	51.49
Ma20ch	2.85%
Net CF	30,479,000
Next Earnings Date	2026-08-12
Open	53.15
Optionable	Yes
Position In Range	61.42
Post Close	52.95
Postmarket Change Percent	0.09
Postmarket Price	$53
Ppne	310,000
Pre Close	52.81
Price Date	2026-07-24
Ptbv Ratio	8.15
Relative Volume	0.31x
Share Based Comp	34,617,000
Tr6m	105.39%
Us State	Colorado
Volume	368,754

Enliven Therapeutics, Inc. (ELVN)

Coverage state: Market snapshot only — no published research

Generate the first ELVN analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ELVN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ELVN indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ELVN

Frequently asked questions